[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.98.119. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
January 28, 1998

Chemokine Receptors and Genetic VariabilityAnother Leap in HIV Research

Author Affiliations

From the Viral Epidemiology Branch (Dr O'Brien), and the Division of Cancer Epidemiology and Genetics (Dr Goedert), National Cancer Institute, US Public Health Service, US Department of Health and Human Services, National Institutes of Health, Bethesda, Md.

JAMA. 1998;279(4):317-318. doi:10.1001/jama.279.4.317

Advances in medicine and public health frequently occur in leaps rather than increments. For example, new therapeutic regimens that dramatically reduce viral replication,1 combined with human immunodeficiency virus type 1 (HIV-1) RNA assays that measure circulating virus and predict the clinical course of HIV-1 infection,2 have led to marked decreases in mortality from the acquired immunodeficiency syndrome (AIDS) in the United States.3 Equally dramatic strides have recently been made in our understanding of how HIV-1 enters cells and how human genetic variability affects susceptibility to infection and clinical prognosis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×